BSO to host prescription drug disposal, document shredding event
The
Broward Sheriff's Office
is set to host a free community event Saturday aimed at combating prescription drug abuse and identity theft, authorities announced.
Dubbed Operation Medicine Cabinet and Shred-A-Thon, the event will run from 10 a.m. to 1 p.m. at the BSO Oakland Park District, located at 5399 North Dixie Highway.
Sheriff Dr. Gregory Tony and his team are urging residents to participate by bringing unused or expired medications and sensitive documents for safe disposal.
The initiative is part of the sheriff's ongoing efforts to address two pressing issues in Broward County.
Residents who turn in prescription medications will receive a $5 gift card while supplies last, though needles and sharp objects will not be accepted.
For document shredding, participants may bring up to two boxes per vehicle, with each box limited to 16 inches long, 12 inches wide, and 12 inches high.
BSO officials say the event reflects their commitment to public safety by reducing the risk of drug misuse and protecting personal information from falling into the wrong hands.
For more information, the sheriff's office directs the public to call 954-831-8902 or visit sheriff.org.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
NEW YORK and CHICAGO, June 10, 2025 /PRNewswire/ -- OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, has selected EVERSANA®, a leading provider of global commercial services to the life sciences industry, to support the U.S. commercialization of OST-HER2, a novel immunotherapy for recurrent, fully resected, pediatric lung metastatic osteosarcoma. OST-HER2, a Listeria monocytogenes-based immunotherapy, is the first potential new treatment in over 40 years for pediatric osteosarcoma, a rare, aggressive bone cancer that often metastasizes to the lungs, primarily affecting children and adolescents. The therapy has received Orphan, Fast Track and Rare Pediatric Disease Designations from the U.S. Food and Drug Administration (FDA), with a Biologics License Application (BLA) rolling submission targeted to begin in the third quarter of 2025, with potential approval coming as early as year end 2025. "Working with EVERSANA ensures we have the infrastructure, expertise and agility to bring OST-HER2 to patients and families who have long awaited new options without the need to spend significant capital building our own commercial infrastructure," said Paul Romness, CEO of OS Therapies. "By leveraging EVERSANA's flexible integrated commercialization operations and deep oncology experience, we will be able to rapidly and cost-effectively fulfill our mission of transforming the treatment landscape for pediatric metastatic osteosarcoma while judiciously managing pre-BLA costs." EVERSANA will activate its dedicated end-to-end EVERSANA ONCOLOGY Commercialization model, including market access, medical affairs, field deployment, patient services and stakeholder engagement. The fully integrated platform accelerates awareness and access to OST-HER2 among healthcare providers treating osteosarcoma, as well as the potential to treat additional HER2-positive cancers. "We share OS Therapies' relentless commitment to helping patients facing the devastating diagnosis of cancer," said Jim Lang, CEO at EVERSANA. "We've activated the full scale of our commercialization operation and global team of oncology experts to bring this much-needed innovation to market. This product is just the beginning of OS Therapies' impact for patients around the world." The announcement follows OS Therapies' recent issuance of U.S. Patent #12,239,738, securing commercial manufacturing exclusivity for OST-HER2 and its broader Listeria-based immunotherapy platform through 2040. About EVERSANA EVERSANA® is a leading independent provider of global services to the life sciences industry. The company's integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit or connect through LinkedIn and X. About OS TherapiesOS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the US Food & Drug Administration and Fast-Track and Orphan Drug designations from the US FDA and European Medicines Agency. The Company has demonstrated positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a BLA to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the US FDA and other risks and uncertainties described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's most recent Annual Report on Form 10-K and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Media Contacts For EVERSANAMatt BraunVice President, Corporate For OS TherapiesJack Doll+1-410-297-7793Irpr@ View original content to download multimedia: SOURCE EVERSANA Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 hours ago
- Yahoo
Help ICE or lose your job, Florida attorney general tells Broward sheriff
Last week Broward Sheriff Gregory Tony said his department will not prioritize arresting undocumented immigrants who haven't committed crimes. On Monday, Florida Attorney General James Uthmeier warned the sheriff that could cost him his job. Uthmeier posted a strongly worded letter Monday morning addressed to Tony on X lambasting remarks the sheriff made during a June 3 Broward County Commission budget workshop meeting, in which he said that there are 'other priorities in this community that I'm focused on, and immigration is not one of them.' 'I don't care what country you're from. If you commit a crime in this county, I'm coming for you,' Tony said during the meeting. 'But what I refuse to do is take this notion that we need to be knocking on doors or arresting children or going into day care centers or restaurants and taking and snatching people off these streets who have been paying taxes and contributing to this society in some positive form regardless of if they are a U.S. citizen or not. It's not within our purview, it's not within our responsibility, and I won't participate in it.' Tony's June 3 comments appear to put him at odds with President Donald Trump's sweeping crackdown on illegal immigration and Gov. Ron DeSantis' efforts to aid in the president's goals. In February, DeSantis touted that all 67 of the state's sheriffs signed a 'Task Force Model' agreement with ICE that gives deputies some immigration authority under the 287(g) program, including the Broward Sheriff's Office. Uthmeier's letter stated that Tony must comply with a Florida Statute that says 'state and local law enforcement agencies and any official responsible for directing or supervising such agency shall use best efforts to support the enforcement of federal immigration law.' 'You are such an official, and therefore must use 'best efforts' to work with federal immigration authorities, including United States Immigration and Customs Enforcement (ICE),' Uthmeier wrote in the letter. 'Your statements to the contrary suggest you misunderstand or intend to flout these requirements under Florida law.' Penalties for failing to adhere to the law, Uthmeier wrote, include 'declaratory and injunctive relief, being held in contempt, or removal from office by the Governor.' Uthmeier doubled down on the threat against Tony's job Monday afternoon with a video posted on X. 'The choice is simple and participation is not optional. State, county and local officials can support and defend the United States and Florida constitutions and the laws therein,' Uthmeier said in the video. 'Or, we will find someone who will.' Uthmeier wrote in his letter that he wanted Tony to 'clarify' his remarks. Tony responded with a letter of his own on Monday, reassuring the attorney general that the Broward Sheriff's Office works closely with ICE to arrest undocumented immigrants who have committed crimes and is in compliance with its agreements with the federal agency. 'It is BSO's priority to address criminal activity within our community, including crimes committed by unauthorized aliens, and to work with our federal partners in this endeavor,' Tony wrote. 'BSO is not only enforcing the law against unauthorized aliens who commit crimes in the community; it is a leader in this effort.' In his letter, Tony told Uthmeier that BSO entered two agreements with ICE in 2019: a 287(g) Warrant Service Office Agreement that authorizes trained deputies to serve ICE warrants to people in jail and a Basic Ordering Agreement to keep federal immigration detainees in the county jail for up to 48 hours to allow ICE to take them into custody. This year, Tony wrote, BSO entered into the 287(g) Task Force Model agreement 'to assist ICE with federal immigration enforcement upon request.' While Tony's letter seems to try to allay the attorney general's concerns, it does not necessarily contradict the comments he made during the June 3 meeting when a county commissioner asked Tony about BSO's role in arresting undocumented immigrants. 'The patch on our sleeve says Broward County. We're not ICE. We're not immigration,' Tony responded. 'I don't work for the Department of Justice. I don't work for the president of the United States. I work for the people of this community.' Tony said in the meeting that BSO is in compliance with state law and the 287(g) agreement. However, he said, while other Florida sheriff's have 'increased the availability of manpower to execute some of these responsibilities that fall under immigration,' BSO has not. Earlier this year Tony told the Sun Sentinel that while BSO does comply with ICE, it does not deploy deputies to find and round up undocumented immigrants who have not committed any crimes. He echoed the same stance during the June 3 meeting. DeSantis appointed Tony, a Democrat, as Broward sheriff in 2019. He won both his bids to keep his job in the 2020 and 2024 elections. Broward is the only firm Democrat stronghold in South Florida. In March, Uthmeier sent a similar threatening message to the Fort Myers City Council after it voted against enrolling in the 287(g) program. 'Failure to correct the Council's actions will result in the enforcement of all applicable civil and criminal penalties, including but not limited to being held in contempt, declaratory or injunctive relief, and removal from office by the Governor,' Uthmeier wrote in a letter. Days later, the city council unanimously reversed its decision.
Yahoo
11 hours ago
- Yahoo
ClavystBio and A*STAR Partner to Grow MedTech Ventures in Singapore
SINGAPORE, June 10, 2025 /PRNewswire/ -- ClavystBio, a life sciences investor and venture builder established by Temasek, and the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to create and grow MedTech ventures in Singapore. This partnership will support venture creation, product development, and commercialisation by bringing together ClavystBio and two national initiatives hosted by A*STAR — MedTech Catapult and the Diagnostics Development Hub (DxD Hub) — along with A*STAR's broader MedTech and venture creation capabilities. The partnership comes amid growing momentum in Singapore's biomedical landscape, with MedTech output reaching S$20 billion in 2023.[1] As Asia's MedTech market is projected to grow to US$225 billion (S$304 billion) by 2030,[2] these efforts aim to better position Singapore-based innovations to scale and enter new markets. Over this two-year partnership, the parties will work towards the co-creation of new MedTech ventures, investments into A*STAR affiliated companies, and fostering collaborations between A*STAR and ClavystBio's portfolio companies. By combining complementary strengths — from research and engineering to venture building and funding — the partnership aims to identify promising technologies, shape MedTech projects for market readiness, and support new venture formation to strengthen Singapore's innovation-driven MedTech ecosystem. The partnership will focus on several key areas: Fostering new ventures from research: A*STAR and ClavystBio will jointly identify promising research and technologies to venture build new MedTech companies. A*STAR will contribute deep scientific expertise and structured venture creation support, while ClavystBio will provide access to venture and growth capital, expert guidance, and its extensive network to launch and scale these early-stage companies. Advancing MedTech product development: MedTech Catapult will support the development of medical devices through engineering design, prototyping, and manufacturing translation, while ClavystBio will draw on its investment and industry relationships to explore potential commercial pathways for promising innovations. Accelerating commercial readiness in diagnostics and digital health: DxD Hub and ClavystBio will shape ventures in this space with strong commercial potential. DxD Hub will bring technical and productisation expertise — including in AI-powered software, multi-omics, and point-of-care diagnostics — to refine innovations for commercial viability. ClavystBio will contribute its venture investing and venture building expertise to drive commercialisation. Strengthening Singapore's MedTech ecosystem: To support long-term sector growth, the partners will assess Singapore's MedTech manufacturing, design, and regulatory support landscape. MedTech Catapult will lead efforts to map ecosystem capabilities and identify gaps, while ClavystBio will explore investment opportunities in companies with specialised technologies that can strengthen Singapore's MedTech value chain. "This partnership highlights ClavystBio's commitment to nurturing globally successful medical devices, digital health, and diagnostics companies from Singapore," said Mr Anselm Tan, Digital Health & MedTech Lead at ClavystBio. "By combining ClavystBio's investment and venture-building expertise with A*STAR's deep scientific capabilities and productisation platforms, we are cultivating an ecosystem primed for innovation and commercial success. "A*STAR is committed to nurturing a dynamic MedTech ecosystem that bridges innovation with deep tech companies," said Ms Irene Cheong, Assistant Chief Executive (Innovation & Enterprise) at A*STAR. "This MoU builds on an existing collaboration with ClavystBio and marks a significant step forward in our joint efforts to co-create and grow globally investible MedTech ventures. Through national productisation platforms like MedTech Catapult and DxD Hub, combined with A*STAR's venture creation capabilities, we aim to commercialise more innovations from lab to market and grow a vibrant MedTech ecosystem in Singapore." [1] Speech by SMS Low Yen Ling at the MedTech Forum[2] Singapore's MedTech sector and locally made medical devices punching above their weight | Singapore EDB About ClavystBio ClavystBio is a life sciences investor and venture builder set up by Temasek to accelerate the commercialization of breakthrough ideas into health impact. We invest and partner with founders and entrepreneurs to launch and grow global companies from Singapore. Our focus spans therapeutics, digital health and medtech, with an emphasis on first-in-class science and technology. Our collaborative space, Node 1, provides plug-and-play spaces for ventures that have graduated from incubators to progress to their next milestones. By bringing start-ups together, we foster a vibrant and supportive community. About the Agency for Science, Technology and Research (A*STAR) The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit About Diagnostics Development Hub (DxD Hub) The Diagnostics Development Hub is a national platform hosted by the Agency for Science, Technology and Research (A*STAR). DxD Hub aims to accelerate the transformation of innovations into clinically validated diagnostic devices that are ready for market adoption. Through impactful products, empowering local enterprises and anchoring global companies in Singapore, DxD Hub contributes to the development of an effective diagnostic devices' ecosystem in Singapore. For ongoing news, visit About MedTech Catapult MedTech Catapult (MC) is a national initiative designed to accelerate the product development and commercialisation of high-value life science instruments and regulated medical devices. MC partners with product owners, local contract manufacturers (CMs), and leverages external design houses, and other key stakeholders to guide innovations from concept to market. Their goal is to strengthen Singapore's medtech ecosystem by providing dedicated engineering, quality assurance, regulatory affairs, clinical affairs, project management and commercialisation support to derisk and support products towards commercialisation and market adoption whilst supporting pull-through to local manufacturing. View original content to download multimedia: SOURCE ClavystBio Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
